Endo Monitor Weight Waist Art

---
name: endo-monitor-weight-waist-art
description: Recommends regular monitoring of weight and waist circumference in patients receiving antiretroviral therapy due to unavoidable weight gain, redistribution, and associated cardiovascular risk. Triggered when a clinician asks, 'How often should I check weight and waist in this patient on ART?' or 'What parameters should I track to detect ART‑related weight changes?'
---

# Monitor weight and waist circumference in patients on antiretroviral therapy

## STEP 1 — Gather Information
Collect baseline weight and waist circumference, current ART regimen and duration, cardiovascular risk factors (diabetes, hypertension, dyslipidemia), and any symptoms of lipodystrophy. Record these values for trend analysis.

## STEP 2 — Rule In / Rule Out
Is the patient currently on antiretroviral therapy? If yes, proceed to ART‑specific weight/waist monitoring; if no, skip ART‑specific monitoring and follow general obesity screening guidelines.

## STEP 3 — Classify or Stratify
Assess weight change (% change from baseline) and waist circumference change (cm change): stable (<3% weight gain and <5 cm waist increase), moderate (3‑5% weight gain or 5‑10 cm waist increase), or high (>5% weight gain or >10 cm waist increase). Assign risk level (low, moderate, high) to guide monitoring frequency and intervention.

## STEP 4 — Decide
For low risk, repeat weight and waist in 6‑12 months; for moderate risk, repeat in 3 months and initiate lifestyle counseling; for high risk, repeat in 1‑3 months, intensify diet/exercise intervention, evaluate for ART switch after confirming virologic suppression, and consider referral to nutrition specialist.

## Clinical Guardrails / Mimics / Pitfalls
Do not rely solely on BMI; waist circumference is essential to detect visceral adiposity. Avoid attributing weight gain exclusively to diet without reviewing ART regimen. Do not delay intervention until overt obesity develops. Avoid changing ART solely for weight gain without confirming viral suppression and exploring adherence.

## Concrete Clinical Example
A 45‑year‑old man on TDF/FTC/EFV for 2 years presents for routine HIV visit. Baseline weight 78 kg, waist 92 kg. Current weight 86 kg (+10%, >5% threshold), waist 102 cm (+10 cm). He reports increased abdominal girth. Weight change >5% and waist increase >10 cm classify as high risk. Action: intensify diet/exercise counseling, consider switching to TAF‑based regimen after confirming viral suppression, and schedule weight/waist recheck in 1 month.

**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI: 10.1210/jc.2014-3415